NCT00016224View on ClinicalTrials.gov

Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

January 31, 2001

Primary Completion Date

March 31, 2004

Study Completion Date

March 31, 2004

Conditions
Ovarian Cancer
Interventions
DRUG

thalidomide

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00016224 - Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer | Biotech Hunter | Biotech Hunter